Extended Adjuvant Therapy in HER2-Positive Disease
Adam M. Brufsky, MD, PhD, and Lynn Acierno, BSN, RN, OCN, RN-BC, provide an overview on the use of neratinib, a targeted therapy, as extended adjuvant therapy in HER2-positive breast cancer. View more at http://curetoday.com/ CURE: Combining science and humanity to make cancer understandable.
